As vaccines roll out, states face difficult questions over access
Charlotte Evans is avidly watching the news about coronavirus vaccines – and as soon as one is available to her, she’ll be lining up to get it.
An elementary school librarian in Rock Hill, South Carolina, Ms. Evans is at work five days a week, seeing six classes a day of children, who are otherwise tightly podded with their classroom teacher.
“This is a hard, hard way to teach,” says Ms. Evans, who also has a diagnosis that puts her in a higher-risk category. “For a lot of us it feels more like a race. Can we get the vaccine before we get COVID?”
Assuming the U.S. Food and Drug Administration approves it, the Pfizer vaccine will likely be available around Dec. 14. Moderna’s could be ready a week later. But with limited availability and high demand, one of the top questions has been just who the vaccines will go to. It’s up to states to make those decisions.
Theory meets practiceGuidelines – and how they can get complicatedMarginalized communities at riskWhat about inmates? Teachers?
